COLL Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 9.32%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Corcept Therapeutics, Inc.'s return on equity of 16%.

Collegium Pharmaceutical, Inc. has a consensus price target of $53.17, signalling upside risk potential of 16.85%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $94.20 which suggests that it could grow by 114.19%. Given that Corcept Therapeutics, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Collegium Pharmaceutical, Inc.'s net income of $31.5M is higher than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.32x while Corcept Therapeutics, Inc.'s PE ratio is 50.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.28x versus 7.09x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 35.57%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Collegium Pharmaceutical, Inc. has a consensus price target of $53.17, signalling upside risk potential of 16.85%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 47.83%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.32x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.28x versus 5.18x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 2.63%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

Collegium Pharmaceutical, Inc. has a consensus price target of $53.17, signalling upside risk potential of 16.85%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $42.15 which suggests that it could grow by 42.32%. Given that Hims & Hers Health, Inc. has higher upside potential than Collegium Pharmaceutical, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Collegium Pharmaceutical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.372, suggesting its more volatile than the S&P 500 by 137.204%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. Collegium Pharmaceutical, Inc.'s net income of $31.5M is higher than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.32x while Hims & Hers Health, Inc.'s PE ratio is 54.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.28x versus 3.33x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.05% compared to Collegium Pharmaceutical, Inc.'s net margin of 27.89%. Collegium Pharmaceutical, Inc.'s return on equity of 24.26% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Collegium Pharmaceutical, Inc. has a consensus price target of $53.17, signalling upside risk potential of 16.85%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $606.43 which suggests that it could grow by 15.73%. Given that Collegium Pharmaceutical, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Collegium Pharmaceutical, Inc. is more attractive than Intuitive Surgical, Inc..

Collegium Pharmaceutical, Inc. has a beta of 0.604, which suggesting that the stock is 39.581% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Collegium Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Collegium Pharmaceutical, Inc. quarterly revenues are $209.4M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Collegium Pharmaceutical, Inc.'s net income of $31.5M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Collegium Pharmaceutical, Inc.'s price-to-earnings ratio is 28.32x while Intuitive Surgical, Inc.'s PE ratio is 66.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical, Inc. is 2.28x versus 18.88x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.